Human Reproduction, Vol. 15, No. 6, 1284-1288,
June 2000
© 2000 European Society of Human Reproduction and Embryology
Experience with progesterone gel for luteal support in a highly successful IVF programme*
*Presented in part at the 55th Annual Meeting of the American Society for Reproductive Medicine, Toronto, Ontario, Canada, September 25–29, 1999.
Colorado Center for Reproductive Medicine, 799 E. Hampden Ave, Englewood, Colorado 80110, USA
Efficacy of luteal support from single daily administration of Crinone® 8% (progesterone gel) was tested in 43 women in an IVF programme with historical pregnancy rates >50%. Results were compared with those achieved in 46 women concurrently undergoing IVF and receiving 50 mg i.m. progesterone, and with historical data. Pregnancy rates (PR) were evaluated approximately 2 weeks after undergoing IVF by human chorionic gonadotrophin (HCG) measurement (total PR), by ultrasound 2–4 weeks later (clinical PR), and by counting births. Prior experience with other progesterone formulations was compared with that of Crinone 8%. Demographic and IVF characteristics were comparable for both concurrently treated groups. Total PR, clinical PR and live birth rates were similar for the Crinone and the concurrent i.m. progesterone groups: 31 (72.1%) versus 34 (73.9%); 26 (60.5%) versus 28 (60.9%), and 23 (53.5%) versus 23 (50%) respectively. Clinical PR and live birth rates were also similar to the last data reported to the Society for Assisted Reproduction Therapy. Overall acceptability of Crinone 8% was excellent. Among subjects with prior i.m. injection experience, most patients (69.2%) agreed that the gel was easier to use, less painful (76.9%) and less time-consuming (61.5%) than i.m. injections. In conclusion, Crinone 8% offers an appreciable improvement, as it provides an effective luteal support option that avoids painful i.m. injections.
Key words: assisted reproduction/Crinone/luteal support/progesterone/vaginal progesterone
1 To whom correspondence should be addressed. E-mail: ccrm{at}colocrm.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Aboulghar, Y. M. Amin, H. G. Al-Inany, M. M. Aboulghar, L. M. Mourad, G. I. Serour, and R. T. Mansour Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks Hum. Reprod., April 1, 2008; 23(4): 857 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Humaidan, H. Ejdrup Bredkjaer, L. Bungum, M. Bungum, M.L. Grondahl, L. Westergaard, and C. Yding Andersen GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study Hum. Reprod., May 1, 2005; 20(5): 1213 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nyboe Andersen, B. Popovic-Todorovic, K.T. Schmidt, A. Loft, A. Lindhard, A. Hojgaard, S. Ziebe, F. Hald, B. Hauge, and B. Toft Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial Hum. Reprod., February 1, 2002; 17(2): 357 - 361. [Abstract] [Full Text] [PDF]
|
|